Fig. 7: CIP2A upregulates Bcl2 in NSCLC cells.

a H1299 and H1975 cells were transfected with pCDH-CIP2A, lysed 48 h later, and cell lysates were subjected to western blot using the indicated antibodies. b H1975 cells were transfected with pCDH-CIP2A, lysed 48 h later, and fractions isolated from different compartments were subjected to western blotting using the indicated antibodies. c pCDH-CIP2A-expressing H1299 cells were treated with carboplatin and cell apoptosis was evaluated with Annexin V-FITC/propidium iodide method. d Western blot analyses of the indicated proteins using lysates from A549 cells that were transfected with shCIP2A. e A549 cells were transfected with shCIP2A, lysed 48 h later, and fractions isolated from different compartments were subjected to western blotting. f A549 cells that were transfected with shCIP2A were inoculated into the right flank of nude mice (5 ×10⁶ cells/mouse), which were euthanized 37 days after cell injection. Tumors were isolated and tumor sections were obtained for IHC assays using the indicated antibodies. g H1299 cells stably expressing shPKM2 were transfected with WT, S287D PKM2, or S287A PKM2, and lysed for western blot analysis. h Cell proliferation was analyzed by an IncuCyte Live-Cell Analysis System. i The cells were inoculated into right flank of the mice, and tumor volume was measured. n = 9 for each group. j Mutations of PKM2 in TCGA NSCLCs. PK, pyruvate kinase, barrel domain (43–395); PK_C: pyruvate kinase, α/β domain (409–529).